Zydus Lifesciences ZYDUSLIFE
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Research path: Interpret Zydus Lifesciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
AI analysis and Advanced tools for ZYDUSLIFE
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 52,406.6 | 37,201.7 | 29,280.8 |
| Accumulated Depreciation Total | -6,424.5 | -5,619.7 | -5,081.8 |
| Other Liabilities Total | 1,522.2 | 1,257 | 1,365.7 |
| Accrued Expenses | 1,836 | 1,748 | 1,270.2 |
| Long Term Debt | 3,188 | Not available | 0 |
| Common Stock Total | 100.6 | 100.6 | 100.6 |
| Other Equity Total | -1,744 | -974.2 | -905.2 |
| Other Current Assets Total | 52.9 | 89.6 | 401.3 |
| Prepaid Expenses | 398.7 | 114.4 | 102.1 |
| Total Assets | 52,406.6 | 37,201.7 | 29,280.8 |
| Current Portof LT Debt/Capital Leases | 4,238.1 | 11.6 | 10.5 |
| Cash | 855.2 | 826.8 | 413 |
| Total Equity | 27,111.4 | 23,953.1 | 19,829.5 |
| Long Term Investments | 1,765.9 | 1,557 | 969.6 |
| Retained Earnings(Accumulated Deficit) | 28,754.8 | 24,826.7 | 20,634.1 |
| Total Common Shares Outstanding | 100.62 | 100.62 | 100.62 |
| Property/Plant/Equipment Total-Gross | 16,820.9 | 12,979.6 | 11,996.6 |
| Tangible Book Valueper Share Common Eq | 96.43 | 153.91 | 118.78 |
| Goodwill Net | 7,542.7 | 5,242.1 | 5,266 |
| Total Liabilities | 25,295.2 | 13,248.6 | 9,451.3 |
| Total Debt | 12,496 | 3,213.2 | 804.2 |
| Short Term Investments | 6,332.6 | 6,977.1 | 940 |
| Cashand Short Term Investments | 7,187.8 | 7,803.9 | 1,353 |
| Total Receivables Net | 6,252.1 | 4,943.5 | 6,047.3 |
| Notes Payable/Short Term Debt | 4,401.6 | 3,169.5 | 768.6 |
| Deferred Income Tax | 1,734 | 512.6 | 446.5 |
| Accounts Receivable-Trade Net | 5,424.1 | 4,039.8 | 5,231.2 |
| Property/Plant/Equipment Total-Net | 10,396.4 | 7,359.9 | 6,914.8 |
| Minority Interest | 2,470.8 | 2,405.3 | 2,272.1 |
| Total Current Liabilities | 15,711.9 | 9,041.6 | 5,341.9 |
| Total Inventory | 6,014.6 | 4,094.7 | 3,597.7 |
| Accounts Payable | 2,845.1 | 2,305.8 | 2,126.7 |
| Other Currentliabilities Total | 2,391.1 | 1,806.7 | 1,165.9 |
| Total Long Term Debt | 3,856.3 | 32.1 | 25.1 |
| Intangibles Net | 9,865.2 | 3,223.6 | 2,611 |
| Other Long Term Assets Total | 2,286.1 | 2,530.4 | 1,842.1 |
| Note Receivable-Long Term | 644.2 | 242.6 | 175.9 |
| Total Current Assets | 19,906.1 | 17,046.1 | 11,501.4 |
| Capital Lease Obligations | 668.3 | 32.1 | 25.1 |
Valuation and ratios
Valuation
PEG Ratio0.6
Price to Sale Ratio4.06
Growth
Debt 5Yr CAGR %22.08
Margins
Operating Margin 12m19.41
Operating Margin 5y Avg19.93
Net Profit Margin 12m18.51
Net Profit Margin 5y17.4
Yield
Dividend Yield %0.09
Source-qualified signals
Risk metrics
Overall RiskModerate risk
Board Risk24.34
Analyst consensus
ConsensusBuy
Consensus score2.53
Analyst opinions30
Strong Sell count2
Sell count3
Hold count10
Buy count9
Strong Buy count6
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Lupin | INR 2,395 | 1.10 L | 19.12 | — |
Ownership
- Promoter
- 75.01%
- FII
- 6.89%
- MF
- 5.12%
- Other
- 12.98%
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Ahead of the buyback opening, Zydus Life stock was trading 2.5% lower at ₹ 1,063 apiece on Tuesday, 2 June. Here are the buyback details, along with experts' opinions on whether retail investors should participate.
Zydus Lifesciences announced an increase in its share buyback pricebut a cut in the number of shares offered. Here's the new buyback price, along with other revised details of the offer.
Zydus Lifesciences shares rose over 6% after strong Q4FY26 earnings, reporting a 14.6% increase in net profit to ₹ 1,592.9 crore. Revenue grew to ₹ 7,587 crore, driven by the consumer wellness segment. The board approved a ₹ 1,100 crore share buyback and a Re 1 dividend.
For FY26, its revenue from operations stood at ₹ 27,148.4 crore, up 17% on-year, and adjusted net profit grew 15% to ₹ 5,456.4 crore.
The Indian stock market rebounded on May 14, with the Sensex up 790 points. Analysts recommend buying stocks like Nippon Life India Asset Management and Zydus Lifesciences, citing strong market conditions despite geopolitical tensions and high oil prices.
Zydus Lifesciences board will meet on May 19 to address potential share buyback details. Market participants are now expected to closely track the size, pricing, and structure of the proposed buyback if approved by the board.
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.0000 per share(100%)Final Dividend
- annual General MeetingBuy Back of Shares
- board MeetingsAudited Results, Dividend & Buy Back
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsInter-alia, to consider 1. Proposal for raising funds up to Rs. 5,000 Crores through the issuance of eligible securities of the Company by way of qualified institutions placement(s), rights issue or any other method...
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.11.0000 per share(1100%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.3.0000 per share(300%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingBuy Back of Shares
- board MeetingsQuarterly Results & Buy Back of shares
Discussion and sentiment for Zydus Lifesciences
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Community discussion loads as you approach this section.
Business information
What the company does
Zydus Lifesciences Limited is an India-based life-sciences company with positions across pharmaceuticals and consumer wellness, supported by a MedTech franchise and a global footprint across United States, India and other international markets. Its pharmaceutical business includes integrated pharmaceutical operations with business encompassing the entire value chain in research, development, production, marketing and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients, human formulations, and animal health and veterinary. Its consumer products business includes development, production, marketing and distribution of differentiated health and wellness products. It provides biologicals manufacturing sites offering contract development and manufacturing organization services to biopharmaceutical companies globally. Its focused therapy areas include cardiology, anti-diabetes, super specialty areas of oncology and nephrology, and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ZYDUSLIFE
- BSE Code
- 532321
Stock FAQ
What is the symbol and ISIN of Zydus Lifesciences?
Zydus Lifesciences has the symbol ZYDUSLIFE and ISIN - INE010B01027.
What is the latest recorded price of Zydus Lifesciences?
The latest available recorded price of Zydus Lifesciences is INR 1,108.00 as of 2026-08-06T20:44:45.879Z. This is a source-stamped snapshot, not a live quote.
What are the year high and year low of Zydus Lifesciences?
Year high: INR 1,181.00. Year low: INR 835.85.
What is the market capitalization of Zydus Lifesciences?
Market capitalization: INR 1.10 lakh crore.
What is the P/E ratio of Zydus Lifesciences?
P/E ratio: 17.39.
What is the dividend yield of Zydus Lifesciences?
Dividend yield: 0.09%.
How is the financial performance of Zydus Lifesciences based on revenue, net income, and EPS?
Revenue: INR 27,148.40 crore. Net income: INR 5,040.00 crore. EPS: INR 54.14.
What is the book value of Zydus Lifesciences?
Book value: INR 96.43.
What are the price-to-book and price-to-sales ratios of Zydus Lifesciences?
Price-to-book ratio: 11.49. Price-to-sales ratio: 4.06.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.